| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
3-Methoxytyramine is a metabolite of dopamine and a neuromodulator. It induces behavioral effects and significant ERK and CREB phosphorylation. The compound is a potential biomarker for pheochromocytomas and paragangliomas. It functions as a human blood serum and urinary metabolite. 3-Methoxytyramine is classified as a phenol, primary amino compound, monomethoxybenzene, and phenylethylamine.
|
|---|---|
| ln Vitro |
In vitro, 3-Methoxytyramine is a metabolite of dopamine and a neuromodulator. It induces significant ERK and CREB phosphorylation in cell-based assays. The compound is used as a biomarker for pheochromocytomas and paragangliomas. Its effects on neuronal signaling have been characterized in various in vitro systems. 3-Methoxytyramine is a human blood serum and urinary metabolite.
|
| ln Vivo |
In mice with dopamine deficiency (DAT-KO; DDD), the extracellular metabolite 3-methoxytyramine (3-MT) causes a considerable behavioral activation. 3-In the striatum of animals lacking dopamine, methyloxytyramine can cause intracellular signaling and behavioral activation [1].
In vivo, 3-Methoxytyramine is a neuromodulator that induces behavioral effects. It is a metabolite of dopamine and a potential biomarker for pheochromocytomas and paragangliomas. The compound induces a complex set of abnormal involuntary movements in dopamine-depleted mice. It functions as a human blood serum and urinary metabolite. 3-Methoxytyramine is used in Parkinson's disease and cancer research. |
| Enzyme Assay |
In vitro enzyme assays for 3-Methoxytyramine involve measuring its role as a dopamine metabolite. Enzymes such as catechol-O-methyltransferase (COMT) convert dopamine to 3-methoxytyramine. Enzyme activity is assessed by measuring the formation of 3-methoxytyramine from dopamine using HPLC or LC-MS. For receptor signaling studies, cells are treated with 3-methoxytyramine and ERK and CREB phosphorylation is assessed by Western blot. Assays are performed in appropriate buffer systems with positive controls such as known neuromodulators.
|
| Cell Assay |
In vitro cell-based assays for 3-Methoxytyramine are conducted in neuronal cell lines and other relevant cell types. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with 3-Methoxytyramine at varying concentrations. ERK and CREB phosphorylation is assessed by Western blot. Behavioral effects are assessed in neuronal models. Cell viability is assessed by standard assays. Experiments are performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
3-Methoxytyramine in vivo studies are conducted in animal models for neurological and cancer research. Animals are administered 3-Methoxytyramine via injection. Behavioral effects are assessed by monitoring movement and activity. ERK and CREB phosphorylation in brain tissues is assessed by Western blot or immunohistochemistry. For biomarker studies, blood and urine levels are measured. Animals are monitored for clinical signs. Tissues and blood samples are collected for biochemical analysis at study endpoints. Studies are conducted in accordance with institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
3-Methoxytyramine (MW 167.21 g/mol, C9H13NO2) is a dopamine metabolite and neuromodulator. It is also known as 3-O-methyldopamine. The compound is soluble in water and other appropriate solvents. It is stable under recommended storage conditions. 3-Methoxytyramine is a potential biomarker for pheochromocytomas and paragangliomas. Pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution would be determined in species-specific studies.
|
| Toxicity/Toxicokinetics |
3-Methoxytyramine is generally well-tolerated as an endogenous metabolite. The compound is a metabolite of dopamine and a neuromodulator. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard laboratory safety practices should be employed when handling this compound. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| References | |
| Additional Infomation |
3-Methoxytyramine is a monomethoxybenzene derivative, a structure of dopamine in which the 3-hydroxyl group is replaced by a methoxy group. It is a metabolite of the neurotransmitter dopamine and is considered a potential biomarker for pheochromocytoma and paraganglioma. It is present in human serum and urine and can serve as a biomarker. It belongs to the phenolic, primary amine, monomethoxybenzene, and phenethylamine classes. Its function is related to dopamine. It is the conjugate base of 3-methoxytyramine. 4-(2-aminoethyl)-2-methoxyphenol has been reported in Senegalia berlandieri, Echinopsis spachiana, and other organisms with relevant data.
3-Methoxytyramine (3-O-methyldopamine) is a metabolite of dopamine and a neuromodulator that induces behavioral effects and ERK and CREB phosphorylation. It is a potential biomarker for pheochromocytomas and paragangliomas. The compound functions as a human blood serum and urinary metabolite. Its molecular formula is C9H13NO2 with a molecular weight of 167.21 g/mol. All applications are limited to non-human research use. |
| Molecular Formula |
C9H13NO2
|
|---|---|
| Molecular Weight |
167.20502
|
| Exact Mass |
167.094
|
| CAS # |
554-52-9
|
| Related CAS # |
3-Methoxytyramine hydrochloride;1477-68-5
|
| PubChem CID |
1669
|
| Appearance |
Yellow to brown solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
304.5±27.0 °C at 760 mmHg
|
| Flash Point |
137.9±23.7 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.559
|
| LogP |
0.43
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
12
|
| Complexity |
130
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
DIVQKHQLANKJQO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H13NO2/c1-12-9-6-7(4-5-10)2-3-8(9)11/h2-3,6,11H,4-5,10H2,1H3
|
| Chemical Name |
4-(2-aminoethyl)-2-methoxyphenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~8.33 mg/mL (~49.82 mM)
H2O : ~2 mg/mL (~11.96 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.56 mg/mL (3.35 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.6 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.56 mg/mL (3.35 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.6 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.9805 mL | 29.9025 mL | 59.8050 mL | |
| 5 mM | 1.1961 mL | 5.9805 mL | 11.9610 mL | |
| 10 mM | 0.5981 mL | 2.9903 mL | 5.9805 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
